PL3416627T3 - Doustna postać dawkowania zawierająca rifaksyminę w postaci beta - Google Patents

Doustna postać dawkowania zawierająca rifaksyminę w postaci beta

Info

Publication number
PL3416627T3
PL3416627T3 PL18718476T PL18718476T PL3416627T3 PL 3416627 T3 PL3416627 T3 PL 3416627T3 PL 18718476 T PL18718476 T PL 18718476T PL 18718476 T PL18718476 T PL 18718476T PL 3416627 T3 PL3416627 T3 PL 3416627T3
Authority
PL
Poland
Prior art keywords
rifaximin
oral dosage
beta
dosage form
form beta
Prior art date
Application number
PL18718476T
Other languages
English (en)
Inventor
Franz Xaver Schwarz
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3416627(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of PL3416627T3 publication Critical patent/PL3416627T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL18718476T 2017-04-26 2018-04-25 Doustna postać dawkowania zawierająca rifaksyminę w postaci beta PL3416627T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17168281 2017-04-26
PCT/EP2018/060547 WO2018197538A1 (en) 2017-04-26 2018-04-25 Oral dosage form comprising rifaximin in form beta
EP18718476.7A EP3416627B9 (en) 2017-04-26 2018-04-25 Oral dosage form comprising rifaximin in form beta

Publications (1)

Publication Number Publication Date
PL3416627T3 true PL3416627T3 (pl) 2020-06-01

Family

ID=58632906

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18718476T PL3416627T3 (pl) 2017-04-26 2018-04-25 Doustna postać dawkowania zawierająca rifaksyminę w postaci beta

Country Status (9)

Country Link
US (1) US11052071B2 (pl)
EP (1) EP3416627B9 (pl)
AU (1) AU2018211305B2 (pl)
CA (1) CA3013161C (pl)
ES (1) ES2774553T3 (pl)
MX (1) MX2018010065A (pl)
PL (1) PL3416627T3 (pl)
SI (1) SI3416627T1 (pl)
WO (1) WO2018197538A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
WO2015173697A1 (en) 2014-05-12 2015-11-19 Alfa Wassermann S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US7252497B2 (en) 2005-03-10 2007-08-07 Husky Injection Molding Systems Ltd. Post-molding molded article conditioning apparatus with a selectively controlled transfer flow structure
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
ES2905795T3 (es) 2007-07-06 2022-04-12 Lupin Ltd Composiciones farmacéuticas de rifaximina
DK2294012T3 (da) * 2008-05-07 2014-10-06 Salix Pharmaceuticals Ltd Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
CN101653428A (zh) * 2008-08-18 2010-02-24 北京瑞伊人科技发展有限公司 利福昔明肠溶制剂组合物及其制备方法
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2014091432A1 (en) * 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
CN103340856A (zh) * 2013-07-09 2013-10-09 荣港生技医药科技（北京）有限公司 一种利福昔明药物组合物及其制备方法
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations

Also Published As

Publication number Publication date
CA3013161A1 (en) 2018-10-26
MX2018010065A (es) 2019-02-07
WO2018197538A1 (en) 2018-11-01
SI3416627T1 (sl) 2020-03-31
US11052071B2 (en) 2021-07-06
EP3416627B9 (en) 2020-04-22
ES2774553T3 (es) 2020-07-21
CA3013161C (en) 2020-03-24
US20190388404A1 (en) 2019-12-26
EP3416627A1 (en) 2018-12-26
EP3416627B1 (en) 2019-11-27
AU2018211305A1 (en) 2018-11-15
AU2018211305B2 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
IL257658B (en) compounds for oral care
IL259211A (en) Oral care tool
IL257659B (en) Oral care compositions
IL259044B (en) compounds for oral care
ZA201807771B (en) Oral care compositions
HK1248994A1 (zh) 牙科椅
ZA201807730B (en) An oral care composition
ZA201706785B (en) Oral care compositions
HK1250679A1 (zh) 口腔用組合物
HK1259305A1 (zh) 口腔護理器具
ZA201803909B (en) Oral care compositions
HK1252141A1 (zh) 口腔用組合物
HK1248584A1 (zh) 口腔用組合物
GB201701400D0 (en) Compound for use in medicine
ZA201902623B (en) Oral care composition
SI3416627T1 (sl) Peroralna odmerna oblika, ki obsega rifaksimin v obliki beta
ZA201704594B (en) Oral delivery product
ZA202004108B (en) Oral care composition
IL273644A (en) Formulations of bendamustine for oral administration
GB2543417B (en) An oral particulate composition
SG11201708597VA (en) Oral care composition
ZA201903378B (en) Oral care composition
ZA201902622B (en) Oral care composition
IL258305A (en) Oral care compositions
ZA201800096B (en) Oral care compositions